Prevalence of, and effect of semaglutide on, features of non-alcoholic steatohepatitis in patients with obesity with and without type 2 diabetes: analysis of data from two randomised placebo-controlled trials using SomaSignal tests

被引：0
|
作者：
Schattenberg, Joern [1 ]
Gronbaek, Henning [2 ]
Kliers, Iris [3 ]
Ladelund, Steen [3 ]
Long, Michelle [3 ]
Nygard, Sune Boris [3 ]
Sanyal, Arun [4 ]
Davies, Melanie [5 ,6 ]
机构：
[1] Univ Med Ctr Mainz, Metab Liver Res Program, Mainz, Germany
[2] Aarhus Univ Hosp, Dept Gastroenterol & Hepatol, Aarhus, Denmark
[3] Novo Nordisk, Soborg, Denmark
[4] Virginia Commonwealth Univ, Sch Med, Div Gastroenterol Hepatol & Nutr, Richmond, VA USA
[5] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England
[6] NIHR Leicester Biomed Res Ctr, Leicester, Leics, England
来源：
JOURNAL OF HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI-469
引用
收藏
页码：S811 / S812
页数：2
相关论文
共 50 条
  • [11] Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
    Harrison, Stephen A.
    Abdelmalek, Manal F.
    Neff, Guy
    Gunn, Nadege
    Guy, Cynthia D.
    Alkhouri, Naim
    Bashir, Mustafa R.
    Freilich, Bradley
    Kohli, Anita
    Khazanchi, Arun
    Sheikh, Muhammad Y.
    Leibowitz, Mark
    Rinella, Mary E.
    Siddiqui, Mohammad S.
    Kipnes, Mark
    Moussa, Sam E.
    Younes, Ziad H.
    Bansal, Meena
    Baum, Seth J.
    Borg, Brian
    Ruane, Peter J.
    Thuluvath, Paul J.
    Gottwald, Mildred
    Khan, Mujib
    Chen, Charles
    Melchor-Khan, Liza
    Chang, William
    DePaoli, Alex M.
    Ling, Lei
    Lieu, Hsiao D.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (07): : 603 - 616
  • [12] Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
    Loomba, Rohit
    Abdelmalek, Manal F.
    Armstrong, Matthew
    Jara, Maximilian
    Kjaer, Mette
    Krarup, Niels
    Lawitz, Eric
    Ratziu, Vlad
    Sanyal, Arun
    Schattenberg, Joern
    Newsome, Philip N.
    JOURNAL OF HEPATOLOGY, 2022, 77 : S10 - S10
  • [13] Effect of canagliflozin on liver function tests in patients with type 2 diabetes and presumed liver fibrosis suggestive of non-alcoholic steatohepatitis
    Meininger, G.
    Polidori, D.
    DIABETOLOGIA, 2017, 60 : S412 - S413
  • [14] Effect of liraglutide on adipose insulin resistance and hepatic de-novo lipogenesis in non-alcoholic steatohepatitis: substudy of a phase 2, randomised placebo-controlled trial
    Armstrong, Matthew
    Hull, Diana
    Guo, Kathy
    Barton, Darren
    Yu, Jinglei
    Tomlinson, Jeremy
    Newsome, Philip
    LANCET, 2014, 383 : 21 - 21
  • [15] Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials
    Salsali, A.
    Kim, G.
    Woerle, H. J.
    Broedl, U. C.
    Hantel, S.
    DIABETES OBESITY & METABOLISM, 2016, 18 (10): : 1034 - 1040
  • [16] Canagliflozin and Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus (CaNAFLD)-A Secondary Analysis of Two Randomized Controlled Trials
    Borisov, Angel
    Kutz, Alexander
    Christ, Emanuel
    Boldanova, Tuyana
    Bernsmeier, Christine
    Heim, Markus
    Ebrahimi, Fahim
    JOURNAL OF HEPATOLOGY, 2021, 75 : S628 - S628
  • [17] Canagliflozin and Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus (CaNAFLD) - A Secondary Analysis of Two Randomized Controlled Trials
    Borisov, Angel
    Kutz, Alexander
    Christ, Emanuel
    Boldanova, Tuyana
    Bernsmeier, Christine
    Heim, Markus
    Ebrahimi, Fahim
    SWISS MEDICAL WEEKLY, 2022, 152 : 8S - 9S
  • [18] Safety of linagliptin in 8778 patients with type 2 diabetes mellitus: pooled analysis of 23 placebo-controlled randomised clinical trials
    Schernthaner, G.
    Khunti, K.
    Patel, S.
    Cheng, K.
    Mattheus, M.
    Woerle, H. -J.
    DIABETOLOGIA, 2014, 57 : S360 - S360
  • [19] Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (vol 394, pg 2184, 2019)
    Younossi, Z. M.
    Ratziu, V
    Loomba, R.
    LANCET, 2020, 396 (10247): : 312 - 312
  • [20] Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials
    Wang, Zeyu
    Du, Huiqing
    Zhao, Ying
    Ren, Yadi
    Ma, Cuihua
    Chen, Hongyu
    Li, Man
    Tian, Jiageng
    Xue, Caihong
    Long, Guangfeng
    Xu, Meidong
    Jiang, Yong
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
12345